Overview
- The Lancet consensus, published on 12 May, formally renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) after roughly 14 years of global consultation.
- Current diagnostic rules remain unchanged for now, using two of three features (oligo‑anovulation, hyperandrogenism, polycystic ovaries or elevated AMH), but the consensus sets a three‑year rollout toward revised guidelines and disease coding by about 2028.
- Clinicians are urging routine metabolic testing such as fasting insulin, glucose tolerance or HbA1c, and lipid panels, and they recommend team‑based care that includes endocrinology, cardiology and primary care rather than only gynecology.
- Some researchers and patient advocates warn the rename could cause confusion, delay diagnosis, and disrupt advocacy, research and tracking unless matched by provider training, clear coding changes and public guidance.
- Public‑health experts in high‑burden settings like India say PMOS must be integrated into national NCD programmes, primary‑care screening and midlife care because local studies show high prevalence and heavy cardiometabolic comorbidity among affected women.